# Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

> **NCT03402841** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 279 (actual)

## Conditions studied

- Non-Germline BRCA Mutated Ovarian Cancer

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03402841
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-30
- **Primary completion:** 2020-10-02
- **Final completion:** 2022-03-10
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402841, "Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03402841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*